An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017
Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long‐term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the p...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 71; no. 2; pp. 444 - 455 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.02.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long‐term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory‐wide CHB cohort in Hong Kong in 2000‐2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients’ first appearance in four time periods: 2000‐2004, 2005‐2009, 2010‐2013, and 2014‐2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000‐2004; 46 ± 17 years in 2005‐2009; 51 ± 16 years in 2010‐2013; and 55 ± 15 years in 2014‐2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT. |
|---|---|
| AbstractList | Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long‐term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory‐wide CHB cohort in Hong Kong in 2000‐2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients’ first appearance in four time periods: 2000‐2004, 2005‐2009, 2010‐2013, and 2014‐2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000‐2004; 46 ± 17 years in 2005‐2009; 51 ± 16 years in 2010‐2013; and 55 ± 15 years in 2014‐2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT. Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long-term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory-wide CHB cohort in Hong Kong in 2000-2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients' first appearance in four time periods: 2000-2004, 2005-2009, 2010-2013, and 2014-2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000-2004; 46 ± 17 years in 2005-2009; 51 ± 16 years in 2010-2013; and 55 ± 15 years in 2014-2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT.Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long-term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory-wide CHB cohort in Hong Kong in 2000-2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients' first appearance in four time periods: 2000-2004, 2005-2009, 2010-2013, and 2014-2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000-2004; 46 ± 17 years in 2005-2009; 51 ± 16 years in 2010-2013; and 55 ± 15 years in 2014-2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT. Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long‐term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory‐wide CHB cohort in Hong Kong in 2000‐2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients’ first appearance in four time periods: 2000‐2004, 2005‐2009, 2010‐2013, and 2014‐2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000‐2004; 46 ± 17 years in 2005‐2009; 51 ± 16 years in 2010‐2013; and 55 ± 15 years in 2014‐2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT. Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long‐term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory‐wide CHB cohort in Hong Kong in 2000‐2017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications, and/or laboratory parameters, were determined according to CHB patients’ first appearance in four time periods: 2000‐2004, 2005‐2009, 2010‐2013, and 2014‐2017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41 ± 15 years in 2000‐2004; 46 ± 17 years in 2005‐2009; 51 ± 16 years in 2010‐2013; and 55 ± 15 years in 2014‐2017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all P < 0.001). Conclusion: CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT. |
| Author | Yip, Terry Cheuk‐Fung Wong, Vincent Wai‐Sun Tse, Yee‐Kit Liang, Lilian Yan Chan, Henry Lik‐Yuen Yuen, Becky Wing‐Yan Hui, Vicki Wing‐Ki Luk, Hester Wing‐Sum Lui, Grace Chung‐Yan Wong, Grace Lai‐Hung |
| Author_xml | – sequence: 1 givenname: Grace Lai‐Hung orcidid: 0000-0002-2863-9389 surname: Wong fullname: Wong, Grace Lai‐Hung organization: The Chinese University of Hong Kong – sequence: 2 givenname: Vincent Wai‐Sun surname: Wong fullname: Wong, Vincent Wai‐Sun organization: The Chinese University of Hong Kong – sequence: 3 givenname: Becky Wing‐Yan surname: Yuen fullname: Yuen, Becky Wing‐Yan organization: The Chinese University of Hong Kong – sequence: 4 givenname: Yee‐Kit surname: Tse fullname: Tse, Yee‐Kit organization: The Chinese University of Hong Kong – sequence: 5 givenname: Hester Wing‐Sum surname: Luk fullname: Luk, Hester Wing‐Sum organization: The Chinese University of Hong Kong – sequence: 6 givenname: Terry Cheuk‐Fung orcidid: 0000-0002-1819-2464 surname: Yip fullname: Yip, Terry Cheuk‐Fung organization: The Chinese University of Hong Kong – sequence: 7 givenname: Vicki Wing‐Ki surname: Hui fullname: Hui, Vicki Wing‐Ki organization: The Chinese University of Hong Kong – sequence: 8 givenname: Lilian Yan surname: Liang fullname: Liang, Lilian Yan organization: The Chinese University of Hong Kong – sequence: 9 givenname: Grace Chung‐Yan surname: Lui fullname: Lui, Grace Chung‐Yan organization: The Chinese University of Hong Kong – sequence: 10 givenname: Henry Lik‐Yuen surname: Chan fullname: Chan, Henry Lik‐Yuen email: hlychan@cuhk.edu.hk organization: The Chinese University of Hong Kong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31237366$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90c9LHDEUB_AgFt1VD_4DEujFHkaTvMn86G1dtCsIFVQ8hkwm40ZmkmmSoeytf0L_xv4lja7tQWhPD5LPe3nkO0e71lmN0DElZ5QQdr7W4xmQCmAHzShnZQbAyS6aEVaSrKZQ76N5CM-EkDpn1R7aB8qghKKYobiwePFk7BO-dePUy2icxa7Dy7V31ii80mM6iybgC_xo4hpfW-W1DC8dSzc435g2XevwGS_wvfbeROc3v378fDStxndxajf4yrsBs_Q6ji5VWh6iD53sgz56qwfo4eryfrnKbr5-uV4ubjKVM4BMNpBXXUFzgE5LVnCpdEslZVLxmhdMQsNBlqQBaGpJKk65ahqdIJR1pxgcoNPt3NG7b5MOUQwmKN330mo3BcFYXtSUkook-vEdfXaTt2k7wYAzDlVFiqRO3tTUDLoVozeD9Bvx5z8T-LQFyrsQvO7-EkrES1YiZSVes0r2_J1VJr4GEL00_f86vpteb_49Wqwub7cdvwG6oaKa |
| CitedBy_id | crossref_primary_10_1016_S1473_3099_20_30133_X crossref_primary_10_1016_j_arth_2022_08_005 crossref_primary_10_1159_000511585 crossref_primary_10_3389_fphys_2023_1176113 crossref_primary_10_3350_cmh_2020_0333 crossref_primary_10_1016_j_cgh_2023_02_004 crossref_primary_10_1007_s12072_021_10271_x crossref_primary_10_1007_s44197_024_00237_1 crossref_primary_10_1111_jgh_15838 crossref_primary_10_1016_j_jhep_2023_12_001 crossref_primary_10_1111_apt_15581 crossref_primary_10_1002_hep_32716 crossref_primary_10_1111_jonm_13787 crossref_primary_10_1016_j_ejim_2022_11_012 crossref_primary_10_1111_hepr_13726 crossref_primary_10_1186_s41256_024_00345_2 crossref_primary_10_1016_j_jhepr_2022_100441 crossref_primary_10_1038_s41575_024_00967_4 crossref_primary_10_1111_jgh_16593 crossref_primary_10_14309_ajg_0000000000001157 crossref_primary_10_1002_hsr2_352 crossref_primary_10_1097_HEP_0000000000001273 crossref_primary_10_1111_apt_16788 crossref_primary_10_17998_jlc_2024_08_03 crossref_primary_10_4274_vhd_galenos_2024_2024_7_4 crossref_primary_10_1177_13596535221082399 crossref_primary_10_1002_mma_10348 crossref_primary_10_1016_j_cgh_2021_05_062 crossref_primary_10_1080_14656566_2022_2144219 crossref_primary_10_1007_s11901_022_00588_y crossref_primary_10_1111_jgh_15664 crossref_primary_10_1016_j_cld_2023_01_014 crossref_primary_10_1017_S0033291720004250 crossref_primary_10_14309_ajg_0000000000000651 crossref_primary_10_1002_cam4_3378 crossref_primary_10_1111_apt_17107 crossref_primary_10_1016_j_jhep_2024_11_019 crossref_primary_10_1111_liv_16028 crossref_primary_10_1186_s12985_021_01491_6 crossref_primary_10_15212_CVIA_2023_0073 crossref_primary_10_3390_cancers13143424 crossref_primary_10_1016_S0140_6736_22_01468_4 crossref_primary_10_1111_apt_16498 crossref_primary_10_1111_jvh_13631 crossref_primary_10_1016_S2468_1253_24_00096_7 crossref_primary_10_1007_s40121_023_00795_0 crossref_primary_10_1097_HEP_0000000000000404 crossref_primary_10_1016_j_cgh_2021_07_036 crossref_primary_10_1093_cid_ciac387 crossref_primary_10_1002_hep4_1923 crossref_primary_10_1016_j_cam_2022_114692 crossref_primary_10_1111_hsc_14066 crossref_primary_10_2147_CIA_S366255 crossref_primary_10_1038_s41746_024_01145_1 crossref_primary_10_1038_s41575_023_00760_9 crossref_primary_10_1017_S095026882300002X crossref_primary_10_1111_apt_16125 crossref_primary_10_1111_jgh_15007 crossref_primary_10_1111_jgh_15249 |
| Cites_doi | 10.1136/gut.2008.157735 10.1111/apt.14341 10.1016/S2468-1253(16)30107-8 10.1016/S2468-1253(16)30024-3 10.1111/apt.14497 10.1136/gutjnl-2011-300342 10.1016/j.jhep.2017.03.021 10.1016/j.cgh.2014.09.050 10.1002/hep.29800 10.1016/j.jhep.2017.06.019 10.1093/infdis/jiz038 10.1016/j.jhep.2017.09.018 10.1080/01621459.1999.10474144 10.1002/hep.26301 10.1016/S2468-1253(18)30056-6 10.1053/j.gastro.2013.02.002 10.1111/apt.12658 10.1586/17474124.2014.909724 10.2215/CJN.06620613 10.3350/cmh.2018.0106 10.1111/apt.14945 10.1016/j.jhep.2011.09.013 10.1002/hep.30246 10.1002/hep.27894 10.1016/S0140-6736(12)61425-1 10.1128/AAC.01064-18 10.1016/j.jhep.2017.11.039 10.1002/hep.28778 10.1007/s12072-015-9675-4 10.1016/j.jhep.2018.05.009 10.1136/gut.2003.033324 10.1111/j.1365-2036.2010.04276.x 10.1056/NEJM199105233242103 |
| ContentType | Journal Article |
| Copyright | 2019 by the American Association for the Study of Liver Diseases. 2020 by the American Association for the Study of Liver Diseases. |
| Copyright_xml | – notice: 2019 by the American Association for the Study of Liver Diseases. – notice: 2020 by the American Association for the Study of Liver Diseases. |
| DBID | AAYXX CITATION NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/hep.30833 |
| DatabaseName | CrossRef PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 455 |
| ExternalDocumentID | 31237366 10_1002_hep_30833 HEP30833 |
| Genre | article Journal Article |
| GeographicLocations | Hong Kong China China |
| GeographicLocations_xml | – name: Hong Kong China – name: China |
| GrantInformation_xml | – fundername: Gilead Sciences funderid: IN-US-988-5290 – fundername: Gilead Sciences grantid: IN-US-988-5290 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI ACZKN AFNMH AGQPQ AHQVU CITATION MEWTI WXSBR ACIJW NPM 7T5 7TM 7TO 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 ADSXY |
| ID | FETCH-LOGICAL-c4233-ab348f61433fea265aced1a12ac59562a3b53a70b33b9a08515cbbe265379fc23 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Tue Aug 05 10:51:36 EDT 2025 Fri Jul 25 21:26:15 EDT 2025 Thu Apr 03 07:06:34 EDT 2025 Tue Jul 01 03:33:56 EDT 2025 Thu Apr 24 22:55:47 EDT 2025 Wed Jan 22 16:36:46 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2019 by the American Association for the Study of Liver Diseases. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4233-ab348f61433fea265aced1a12ac59562a3b53a70b33b9a08515cbbe265379fc23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2863-9389 0000-0002-1819-2464 |
| PMID | 31237366 |
| PQID | 2352538806 |
| PQPubID | 996352 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2246911080 proquest_journals_2352538806 pubmed_primary_31237366 crossref_primary_10_1002_hep_30833 crossref_citationtrail_10_1002_hep_30833 wiley_primary_10_1002_hep_30833_HEP30833 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2020 |
| PublicationDateYYYYMMDD | 2020-02-01 |
| PublicationDate_xml | – month: 02 year: 2020 text: February 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2020 |
| Publisher | Wolters Kluwer Health, Inc |
| Publisher_xml | – name: Wolters Kluwer Health, Inc |
| References | 2015; 13 2012; 61 2010; 31 2017; 66 2017; 46 2017; 67 2016; 10 2013; 144 2018; 62 2018; 67 2012; 56 2013; 381 2018; 48 2018; 47 2018; 69 2018; 68 2009; 58 2004; 53 2018; 3 2013; 58 2016; 1 2010; 1 2019; 42 2015; 62 2019; 69 2019; 25 2016; 64 2019; 219 1999; 94 2014; 39 2014; 9 2014; 8 1991; 324 (hep30833-bib-0013-20241017) 2010; 1 (hep30833-bib-0024-20241017) 2018; 68 (hep30833-bib-0007-20241017) 2015; 62 (hep30833-bib-0010-20241017) 2009; 58 (hep30833-bib-0020-20241017) 2018; 48 (hep30833-bib-0036-20241017) 2004; 53 (hep30833-bib-0011-20241017) 2016; 64 (hep30833-bib-0023-20241017) 2016; 1 (hep30833-bib-0034-20241017) 2014; 39 (hep30833-bib-0029-20241017) 2012; 61 (hep30833-bib-0004-20241017) 2013; 58 (hep30833-bib-0030-20241017) 2018; 69 (hep30833-bib-0001-20241017) 2018; 3 (hep30833-bib-0017-20241017) 2010; 31 (hep30833-bib-0006-20241017) 2018; 47 (hep30833-bib-0027-20241017) 2019; 25 (hep30833-bib-0018-20241017) 2017; 46 (hep30833-bib-0019-20241017) 1999; 94 (hep30833-bib-0031-20241017) 2016; 10 (hep30833-bib-0033-20241017) 2013; 381 (hep30833-bib-0014-20241017) 2017; 67 (hep30833-bib-0009-20241017) 2018; 67 (hep30833-bib-0002-20241017) 2019; 69 (hep30833-bib-0032-20241017) 2012; 56 (hep30833-bib-0003-20241017) 2013; 144 (hep30833-bib-0035-20241017) 2019; 219 (hep30833-bib-0005-20241017) 2014; 8 (hep30833-bib-0008-20241017) 2017; 67 (hep30833-bib-0015-20241017) 2018; 68 (hep30833-bib-0025-20241017) 2018; 62 (hep30833-bib-0012-20241017) 2014; 9 (hep30833-bib-0021-20241017) 1991; 324 (hep30833-bib-0028-20241017) 2017; 66 (hep30833-bib-0016-20241017) 2019; 42 (hep30833-bib-0022-20241017) 2016; 1 (hep30833-bib-0026-20241017) 2015; 13 |
| References_xml | – volume: 68 start-page: 63 year: 2018 end-page: 72 article-title: Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue‐treated patients publication-title: J Hepatol – volume: 42 start-page: S13 issue: Suppl 1 year: 2019 end-page: S28 article-title: Classification and diagnosis of diabetes: standards of medical care in diabetes—2019 publication-title: Diabetes Care – volume: 381 start-page: 468 year: 2013 end-page: 475 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study publication-title: Lancet – volume: 1 start-page: 196 year: 2016 end-page: 206 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg‐negative chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial publication-title: Lancet Gastroenterol Hepatol – volume: 66 start-page: S25 issue: Suppl year: 2017 article-title: Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 trials in HBeAg‐positive and HBeAg‐neagtive patients with chronic hepatitis B publication-title: J Hepatol – volume: 53 start-page: 1494 year: 2004 end-page: 1498 article-title: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma publication-title: Gut – volume: 69 start-page: 959 year: 2019 end-page: 973 article-title: Advancing age and comorbidity in a United States insured population‐based cohort of patients with chronic hepatitis B publication-title: Hepatology – volume: 62 start-page: e01064‐18 year: 2018 article-title: No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection publication-title: Antimicrob Agents Chemother – volume: 58 start-page: 1537 year: 2013 end-page: 1547 article-title: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis publication-title: Hepatology – volume: 10 start-page: 1 year: 2016 end-page: 98 article-title: Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update publication-title: Hepatol Int – volume: 13 start-page: 783 year: 2015 end-page: 790.e1 article-title: Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B publication-title: Clin Gastroenterol Hepatol – volume: 3 start-page: 383 year: 2018 end-page: 403 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol – volume: 67 start-page: 370 year: 2017 end-page: 398 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – volume: 25 start-page: 172 year: 2019 end-page: 180 article-title: Unmet need in chronic hepatitis B management publication-title: Clin Mol Hepatol – volume: 219 start-page: 1924 year: 2019 end-page: 1933 article-title: A territory‐wide prevalence study on blood‐borne and enteric viral hepatitis in Hong Kong publication-title: J Infect Dis – volume: 144 start-page: 933 year: 2013 end-page: 944 article-title: Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment publication-title: Gastroenterology – volume: 58 start-page: 111 year: 2009 end-page: 117 article-title: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B publication-title: Gut – volume: 8 start-page: 607 year: 2014 end-page: 622 article-title: Current developments in nucleoside/nucleotide analogues for hepatitis B publication-title: Expert Rev Gastroenterol Hepatol – volume: 61 start-page: 409 year: 2012 end-page: 415 article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography publication-title: Gut – volume: 1 start-page: 1468 year: 2010 article-title: Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong publication-title: MEDINFO – volume: 67 start-page: 902 year: 2017 end-page: 908 article-title: Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance publication-title: J Hepatol – volume: 46 start-page: 1001 year: 2017 end-page: 1010 article-title: Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis publication-title: Aliment Pharmacol Ther – volume: 56 start-page: 533 year: 2012 end-page: 540 article-title: Hepatitis B virus infection and fatty liver in the general population publication-title: J Hepatol – volume: 62 start-page: 684 year: 2015 end-page: 693 article-title: Long‐term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B—a cohort study of 53,500 subjects publication-title: Hepatology – volume: 67 start-page: 1560 year: 2018 end-page: 1599 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology – volume: 64 start-page: 1507 year: 2016 end-page: 1517 article-title: Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B publication-title: Hepatology – volume: 31 start-page: 1095 year: 2010 end-page: 1103 article-title: Development of a non‐invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B publication-title: Aliment Pharmacol Ther – volume: 1 start-page: 185 year: 2016 end-page: 195 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg‐positive chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial publication-title: Lancet Gastroenterol Hepatol – volume: 94 start-page: 496 year: 1999 end-page: 509 article-title: A proportional hazards model for the subdistribution of a competing risk publication-title: J Am Stat Assoc – volume: 48 start-page: 984 year: 2018 end-page: 992 article-title: Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment publication-title: Aliment Pharmacol Ther – volume: 68 start-page: 672 year: 2018 end-page: 681 article-title: 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection publication-title: J Hepatol – volume: 47 start-page: 730 year: 2018 end-page: 737 article-title: Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B publication-title: Aliment Pharmacol Ther – volume: 69 start-page: 793 year: 2018 end-page: 802 article-title: Normal on‐treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B publication-title: J Hepatol – volume: 39 start-page: 883 year: 2014 end-page: 893 article-title: Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations publication-title: Aliment Pharmacol Ther – volume: 9 start-page: 779 year: 2014 end-page: 787 article-title: Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications publication-title: Clin J Am Soc Nephrol – volume: 324 start-page: 1457 year: 1991 end-page: 1463 article-title: Membranous nephropathy related to hepatitis B virus in adults publication-title: N Engl J Med – volume: 58 start-page: 111 year: 2009 ident: hep30833-bib-0010-20241017 article-title: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B publication-title: Gut doi: 10.1136/gut.2008.157735 – volume: 46 start-page: 1001 year: 2017 ident: hep30833-bib-0018-20241017 article-title: Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14341 – volume: 1 start-page: 196 year: 2016 ident: hep30833-bib-0022-20241017 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg‐negative chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30107-8 – volume: 42 start-page: S13 issue: Suppl 1 year: 2019 ident: hep30833-bib-0016-20241017 article-title: Classification and diagnosis of diabetes: standards of medical care in diabetes—2019 publication-title: Diabetes Care – volume: 1 start-page: 185 year: 2016 ident: hep30833-bib-0023-20241017 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg‐positive chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30024-3 – volume: 47 start-page: 730 year: 2018 ident: hep30833-bib-0006-20241017 article-title: Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14497 – volume: 61 start-page: 409 year: 2012 ident: hep30833-bib-0029-20241017 article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography publication-title: Gut doi: 10.1136/gutjnl-2011-300342 – volume: 67 start-page: 370 year: 2017 ident: hep30833-bib-0008-20241017 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 13 start-page: 783 year: 2015 ident: hep30833-bib-0026-20241017 article-title: Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.09.050 – volume: 67 start-page: 1560 year: 2018 ident: hep30833-bib-0009-20241017 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology doi: 10.1002/hep.29800 – volume: 67 start-page: 902 year: 2017 ident: hep30833-bib-0014-20241017 article-title: Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance publication-title: J Hepatol doi: 10.1016/j.jhep.2017.06.019 – volume: 219 start-page: 1924 year: 2019 ident: hep30833-bib-0035-20241017 article-title: A territory‐wide prevalence study on blood‐borne and enteric viral hepatitis in Hong Kong publication-title: J Infect Dis doi: 10.1093/infdis/jiz038 – volume: 68 start-page: 63 year: 2018 ident: hep30833-bib-0015-20241017 article-title: Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue‐treated patients publication-title: J Hepatol doi: 10.1016/j.jhep.2017.09.018 – volume: 94 start-page: 496 year: 1999 ident: hep30833-bib-0019-20241017 article-title: A proportional hazards model for the subdistribution of a competing risk publication-title: J Am Stat Assoc doi: 10.1080/01621459.1999.10474144 – volume: 58 start-page: 1537 year: 2013 ident: hep30833-bib-0004-20241017 article-title: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis publication-title: Hepatology doi: 10.1002/hep.26301 – volume: 3 start-page: 383 year: 2018 ident: hep30833-bib-0001-20241017 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30056-6 – volume: 1 start-page: 1468 year: 2010 ident: hep30833-bib-0013-20241017 article-title: Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong publication-title: MEDINFO – volume: 144 start-page: 933 year: 2013 ident: hep30833-bib-0003-20241017 article-title: Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.02.002 – volume: 39 start-page: 883 year: 2014 ident: hep30833-bib-0034-20241017 article-title: Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12658 – volume: 8 start-page: 607 year: 2014 ident: hep30833-bib-0005-20241017 article-title: Current developments in nucleoside/nucleotide analogues for hepatitis B publication-title: Expert Rev Gastroenterol Hepatol doi: 10.1586/17474124.2014.909724 – volume: 9 start-page: 779 year: 2014 ident: hep30833-bib-0012-20241017 article-title: Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.06620613 – volume: 25 start-page: 172 year: 2019 ident: hep30833-bib-0027-20241017 article-title: Unmet need in chronic hepatitis B management publication-title: Clin Mol Hepatol doi: 10.3350/cmh.2018.0106 – volume: 66 start-page: S25 issue: Suppl year: 2017 ident: hep30833-bib-0028-20241017 article-title: Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 trials in HBeAg‐positive and HBeAg‐neagtive patients with chronic hepatitis B publication-title: J Hepatol – volume: 48 start-page: 984 year: 2018 ident: hep30833-bib-0020-20241017 article-title: Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14945 – volume: 56 start-page: 533 year: 2012 ident: hep30833-bib-0032-20241017 article-title: Hepatitis B virus infection and fatty liver in the general population publication-title: J Hepatol doi: 10.1016/j.jhep.2011.09.013 – volume: 69 start-page: 959 year: 2019 ident: hep30833-bib-0002-20241017 article-title: Advancing age and comorbidity in a United States insured population‐based cohort of patients with chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.30246 – volume: 62 start-page: 684 year: 2015 ident: hep30833-bib-0007-20241017 article-title: Long‐term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B—a cohort study of 53,500 subjects publication-title: Hepatology doi: 10.1002/hep.27894 – volume: 381 start-page: 468 year: 2013 ident: hep30833-bib-0033-20241017 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 – volume: 62 start-page: e01064‐18 year: 2018 ident: hep30833-bib-0025-20241017 article-title: No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01064-18 – volume: 68 start-page: 672 year: 2018 ident: hep30833-bib-0024-20241017 article-title: 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.11.039 – volume: 64 start-page: 1507 year: 2016 ident: hep30833-bib-0011-20241017 article-title: Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.28778 – volume: 10 start-page: 1 year: 2016 ident: hep30833-bib-0031-20241017 article-title: Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update publication-title: Hepatol Int doi: 10.1007/s12072-015-9675-4 – volume: 69 start-page: 793 year: 2018 ident: hep30833-bib-0030-20241017 article-title: Normal on‐treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B publication-title: J Hepatol doi: 10.1016/j.jhep.2018.05.009 – volume: 53 start-page: 1494 year: 2004 ident: hep30833-bib-0036-20241017 article-title: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma publication-title: Gut doi: 10.1136/gut.2003.033324 – volume: 31 start-page: 1095 year: 2010 ident: hep30833-bib-0017-20241017 article-title: Development of a non‐invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2010.04276.x – volume: 324 start-page: 1457 year: 1991 ident: hep30833-bib-0021-20241017 article-title: Membranous nephropathy related to hepatitis B virus in adults publication-title: N Engl J Med doi: 10.1056/NEJM199105233242103 |
| SSID | ssj0009428 |
| Score | 2.5534267 |
| Snippet | Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 444 |
| SubjectTerms | Aging Antiviral drugs Cardiovascular diseases Demography Diabetes Diabetes mellitus Health care Hepatitis Hepatitis B Hepatology Hypertension Interferon Kidney diseases Malignancy Osteopenia Osteoporosis Patients |
| Title | An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017 |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.30833 https://www.ncbi.nlm.nih.gov/pubmed/31237366 https://www.proquest.com/docview/2352538806 https://www.proquest.com/docview/2246911080 |
| Volume | 71 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hDohLW_rcFiq36oFLIGs78YaelorVCokKVSA4VIpsxxYrIKl2s4f2xE_gN_JLOuM8EH1IVU-JlLGc2J7xN5nxNwAfNEIKlXoTpcKFMKOOtB8VERfKKiO9554cxaPP6fRUHp4n5yvwsTsL0_BD9D_cSDOCvSYF12axe08aeuHQYUcAQUyflKtFgOjLPXVUJkNdVfS6YoouZx2rUMx3-5YP96LfAOZDvBo2nMlj-Nq9apNncrmzrM2O_fELi-N_fssTeNQCUTZuVs4GrLjyKawdtaH2Z1CPSzamCkbsuK_xxSrPWjZdNnWUi13PFmyfnc3qC4aWhhLcqQUamWpuZkVga91jY3ZC_I8Uzr-7uT2bFY5R-uJ3NplX14xO8bC6wutQPYfTycHJp2nUlmiILOIwEWkj5MjjFi-Ed5qnibauGOoh1zZBz4trYRKhVWyEMJkmeJdYYxwKCpV5y8ULWC2r0r0CZoXk-EwhwkilsvGoiNH2SemEjs1wpAew3U1Wblv-ciqjcZU3zMs8x1HMwygO4H0v-q0h7fiT0GY343mrt4ucEzss8eOkA3jXP0aNozCKLl21RBku04xOT8QDeNmslL4XgUBAiRRbb4f5_nv3-fTgONy8_nfRN7DOyd0PSeObsFrPl24LMVFt3obF_xN2FwTq |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVgIuUN5LCxjEoZe0WdtJNojLAl0F6FYV2qq9VJHt2OoKSNA2e4BTfwK_kV_CjPOoykNCnBLJYzmxPfY3nvE3AM8VQookdjqIhfVuRhUoNyoCLhKTaOkcd2QoTvfj7FC-O46OV-Bldxem4YfoD9xIM_x6TQpOB9I7F6yhpxYtdkQQ4gqsUUZvYs5_8-GCPCqVPrMq2l0h-ZfTjlco5Dt91cu70W8Q8zJi9VvO5CacdB_bRJp83F7Wett8-4XH8X__Zh1utFiUjZvJcwtWbHkbrk5bb_sdqMclG1MSI3bQp_lilWMtoS7LLIVj1_Mz9oodzetThosNxbhTDVxnqoWeF56w9QUbsxlRQJJH_8f596N5YRlFMH5lk0X1mdFFHlZX-Bwmd-Fwsjt7nQVtlobAIBQTgdJCjhzu8kI4q3gcKWOLoRpyZSI0vrgSOhIqCbUQOlWE8CKjtUVBkaTOcHEPVsuqtA-AGSE5liUIMmKZmHBUhLj8SWmFCvVwpAaw1Y1WbloKc8qk8SlvyJd5jr2Y-14cwLNe9EvD2_Enoc1uyPNWdc9yTgSxRJETD-BpX4xKR54UVdpqiTJcxildoAgHcL-ZKn0rArFAImKsveUH_O_N59nugX95-O-iT-BaNpvu5Xtv999vwHVO1r-PId-E1XqxtI8QItX6sdeEn8SqCQY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceD8WChjEoZe0WdtxNnBaaFfLo9UKtWoPSJHt2OqqJam22QOc-An8Rn4JM86jKg8JcUqkjOXE9oy_yYy_AXihEVKkyptICRfCjDrSflREXKQ2NdJ77slR3N1T0wP57ig5WoFX3VmYhh-i_-FGmhHsNSn4WeG3LkhDjx067AggxBW4KlWcUd2G7Y8X3FGZDIVV0e2KKbycdbRCMd_qm17ejH5DmJcBa9hxJjfgU_euTaLJyeayNpv26y80jv_5MTfheotE2bhZOrdgxZW3YW23jbXfgXpcsjGVMGKzvsgXqzxr6XTZ1FEydj0_Z6_Z4bw-ZmhqKMOdWqCVqRZmXgS61pdszPaJAJLi-T--fT-cF45R_uIXNllUnxkd42F1hddhehcOJjv7b6ZRW6MhsgjERKSNkCOPe7wQ3mmuEm1dMdRDrm2CrhfXwiRCp7ERwmSa8F1ijXEoKNLMWy7uwWpZle4BMCskx2cpQgwlUxuPihiNn5RO6NgMR3oAG91k5bYlMKc6Gqd5Q73McxzFPIziAJ73omcNa8efhNa7Gc9bxT3POdHDEkGOGsCz_jGqHMVRdOmqJcpwqTI6PhEP4H6zUvpeBCKBVChsvRHm--_d59OdWbh5-O-iT2Fttj3JP7zde_8IrnFy_UMC-Tqs1oule4z4qDZPgh78BJ-fB7U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Aging+Population+of+Chronic+Hepatitis+B+With+Increasing+Comorbidities%3A+A+Territory%E2%80%90Wide+Study+From+2000+to+2017&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Grace+Lai%E2%80%90Hung+Wong&rft.au=Vincent+Wai%E2%80%90Sun+Wong&rft.au=Becky+Wing%E2%80%90Yan+Yuen&rft.au=Yee%E2%80%90Kit+Tse&rft.date=2020-02-01&rft.pub=Wolters+Kluwer+Health%2C+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=71&rft.issue=2&rft.spage=444&rft.epage=455&rft_id=info:doi/10.1002%2Fhep.30833&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |